Angina (Angina Pectoris) - Pipeline Review, H1 2012

Angina (Angina Pectoris) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Angina (Angina Pectoris) - Pipeline Review, H1 2012', provides an overview of the Angina (Angina Pectoris) therapeutic pipeline. This report provides information on the therapeutic development for Angina (Angina Pectoris), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris). 'Angina (Angina Pectoris) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Angina (Angina Pectoris).
- A review of the Angina (Angina Pectoris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Angina (Angina Pectoris) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Angina (Angina Pectoris).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Angina (Angina Pectoris) pipeline depth and focus of Angina (Angina Pectoris) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Angina (Angina Pectoris) Therapeutic Products under Development, Key Players in Angina (Angina Pectoris) Therapeutics, Angina (Angina Pectoris) Pipeline Overview, Angina (Angina Pectoris) Pipeline, Angina (Angina Pectoris) Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Angina (Angina Pectoris) Overview
Therapeutics Development
An Overview of Pipeline Products for Angina (Angina Pectoris)
Angina (Angina Pectoris) Therapeutics under Development by Companies
Angina (Angina Pectoris) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Angina (Angina Pectoris) Therapeutics – Products under Development by Companies
Angina (Angina Pectoris) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Angina (Angina Pectoris) Therapeutics Development
Cardium Therapeutics, Inc.
Merck & Co., Inc.
Ark Therapeutics Group plc
Bayer AG
Torrent Pharmaceuticals Limited
Circ Pharma Limited
Anthera Pharmaceuticals‚ Inc.
HUYA Bioscience International, LLC
Lacer, S.A.
Viromed Co., Ltd.
Baxter Healthcare Corporation
Angina (Angina Pectoris) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MK-0974 - Drug Profile
EG011 - Drug Profile
Generx - Drug Profile
LA-419 - Drug Profile
A-002 - Drug Profile
VM202 - Drug Profile
T89 - Drug Profile
Clopidogrel for Post-PCI Myonecrosis - Drug Profile
Adenosine - Drug Profile
Sertraline + Omega-3 - Drug Profile
Adenosin - Drug Profile
Fondaparinux - Drug Profile
Folic acid + Tetrahydrobiopterin - Drug Profile
Adenosine A1 Agonist - Drug Profile
Capsaicin - Drug Profile
IS5MN PM - Drug Profile
Bisoprolol PM - Drug Profile
CD34 + Adult Stem Cell Injection - Drug Profile
HBI-3000 - Drug Profile
HBI-3000 - Drug Profile
Endocardial Adenovirus VEGF-D Gene Therapy - Drug Profile
Adult Autologous CD34+ Stem Cells - Drug Profile
TRC-2XXX - Drug Profile
Angina (Angina Pectoris) Therapeutics – Drug Profile Updates
Angina (Angina Pectoris) Therapeutics – Discontinued Products
Angina (Angina Pectoris) Therapeutics - Dormant Products
Angina (Angina Pectoris) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Angina (Angina Pectoris), H1 2012
Products under Development for Angina (Angina Pectoris) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Cardium Therapeutics, Inc., H1 2012
Merck & Co., Inc., H1 2012
Ark Therapeutics Group plc, H1 2012
Bayer AG, H1 2012
Torrent Pharmaceuticals Limited, H1 2012
Circ Pharma Limited, H1 2012
Anthera Pharmaceuticals‚ Inc., H1 2012
HUYA Bioscience International, LLC, H1 2012
Lacer, S.A., H1 2012
Viromed Co., Ltd., H1 2012
Baxter Healthcare Corporation, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Angina (Angina Pectoris) Therapeutics – Drug Profile Updates
Angina (Angina Pectoris) Therapeutics – Discontinued Products
Angina (Angina Pectoris) Therapeutics – Dormant Products
Angina (Angina Pectoris) Therapeutics – Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Angina (Angina Pectoris), H1 2012
Products under Development for Angina (Angina Pectoris) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012